Can-Fite is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has diverse pipeline of proprietary compounds that address inflammatory, ophthalmic, cancer and viral diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells.

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3 adenosine receptor. All drugs are orally bioavailable with an excellent safety profile. The company’s lead drugs are CF101 and CF102, both are small-molecule oral drugs that are safe and very well tolerated. CF101 has shown activity in Psoriasis, Dry Eye Syndrome and Rheumatoid Arthritis in Phase II studies. CF102, is currently being tested in two Phase I/II studies: one in hepatocellular carcinoma and the other in patients with hepatitis C viral infection.


Latest News Events   Israeli office USA office

Morningside and Can Fite BioPharma to Establish a Joint Venture to Develop and Commercialize Can-Fite’s CF102 Drug for the Treatment of Liver Diseases. January 19, 2009

Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma. December 13, 2009

Following the successful completion of two phase II clinical trials, Can Fite BioPharma retains Plexus Ventures to Partner their Phase II Lead Compound, Developed for Psoriasis and Other Indications. November 24, 2009

Can-Fite Initiates Preparatory Work for Psoriasis Phase III Trial with CF101 September 29, 2009

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101. September 7, 2009

Can-Fite Announces Positive Results from its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) with CF101. Dry Eye affects more than 20 million people in the US alone. May 17, 2009

more...

Can-Fite BioPharma to present at:
ACR/ARHP Scientific Meeting 2009, Philadelphia, Oct 17-21, 2009
Poster Presentation:
The A3 Adenosine Receptor as a Biological Predictive Marker in Rheumatoid Arthritis: Lessons from Phase II Clinical Studies

14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine, October 15-17, 2009, Loutraki, Greece
Podium Presentation:
CF102 for the Treatment of Hepatocellular Carcinoma (HCC): From Bench to Bedside

 

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL

Tel: +972-3-9241114
Fax: +972-3-9249378

General email: info@canfite.co.il

Press inquiries:
   Eisenberg-Eliash LTD.,   
   Tel: +972-3-7538828

91 Hartwell Ave.
Lexington
MA 02421
USA


Tel: +1-781-7780417
Fax: +1-781-7780490